Latest Antisense news

Latest Antisense
News & Updates.

4 weeks ago

Results of Annual General Meeting

4 weeks ago

Annual General Meeting 2023 Presentation

2 months ago

Online Meeting Guide for Annual General Meeting 15 November 2023

2 months ago

Notice of Annual General Meeting/Proxy Form

2 months ago

Antisense to participate in upcoming Industry Conferences

2 months ago

Launch of Share Sale Facility for Unmarketable Parcels

2 months ago

New Data Published, and Patent Filed, for ATL1102 in ‘Long COVID’

2 months ago

New Preclinical Data in ATL1102 for Limb Girdle Muscular Dystrophy R2

4 months ago

Antisense Share Purchase Plan raises $3.26M

4 months ago

Commencement of Chief Executive Officer

5 months ago

Positive new DMD Combination Therapy Data in mdx mice

5 months ago

Intention to launch Share Purchase Plan

5 months ago

Institutional Placement and proposed Share Purchase Plan

6 months ago

MHRA Approval Received to Conduct Phase IIb Trial in the UK for ATL1102 in DMD

6 months ago

First Patient Dosed in ATL1102 Phase IIb Duchenne Muscular Dystrophy (DMD) Trial